NCT01849562View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

April 30, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Sovaprevir

Nonstructural protein 3/4A protease inhibitor.

DRUG

ACH-3102

Nonstructural protein 5A inhibitor.

DRUG

Ribavirin

DRUG

Placebo

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY